Success Metrics

Clinical Success Rate
100.0%

Based on 25 completed trials

Completion Rate
100%(25/25)
Active Trials
0(0%)
Results Posted
32%(8 trials)

Phase Distribution

Ph phase_1
16
64%
Ph phase_3
8
32%

Phase Distribution

16

Early Stage

0

Mid Stage

8

Late Stage

Phase Distribution24 total trials
Phase 1Safety & dosage
16(66.7%)
Phase 3Large-scale testing
8(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

25 of 25 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

25

all time

Status Distribution
Completed(25)

Detailed Status

Completed25

Development Timeline

Analytics

Development Status

Total Trials
25
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 116 (66.7%)
Phase 38 (33.3%)

Trials by Status

completed25100%

Recent Activity

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT03987802

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Completed
NCT03268005Phase 3

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Completed
NCT02825251Phase 3

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

Completed
NCT01831765Phase 3

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Completed
NCT01850615Phase 3

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Completed
NCT02500706Phase 3

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Completed
NCT02670915Phase 3

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

Completed
NCT02933853Phase 1

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Completed
NCT03215498Phase 1

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Completed
NCT01819129Phase 3

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Completed
NCT01618188Phase 1

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Completed
NCT01934712Phase 1

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Completed
NCT02568280Phase 1

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Completed
NCT02003677Phase 1

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Completed
NCT01999322Phase 3

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

Completed
NCT02035371Phase 1

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Completed
NCT02089451Phase 1

A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects

Completed
NCT02033239Phase 1

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

Completed
NCT01924637Phase 1

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Completed
NCT01121276Phase 1

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Completed

Drug Details

Intervention Type
DRUG
Total Trials
25